Literature DB >> 12877673

Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome.

June-Won Cheong1, Ju In Eom, Ho-Young Maeng, Seung Tae Lee, Jee Sook Hahn, Yun Woong Ko, Yoo Hong Min.   

Abstract

Phosphorylation of PTEN (phosphatase and tensin homologue) affects PTEN protein stability and function. In this study, phosphorylated PTEN (pPTEN) was observed in 45 (73.8%) of 61 cases with acute myeloid leukaemia (AML). Phosphorylation of Akt and its downstream molecules [FKHR; Forkhead (Drosophila) homologue 1; and GSK-3beta; glycogen synthase kinase 3 beta] was significantly associated with pPTEN (P < 0.001). The complete remission rates were not different with respect to pPTEN, but overall survival was significantly shorter in patients with pPTEN (P < 0.05). Constitutive PTEN phosphorylation may add insight into the molecular pathogenesis of AML, and may be a new parameter for an unfavourable outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877673     DOI: 10.1046/j.1365-2141.2003.04452.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  mTOR regulates cell survival after etoposide treatment in primary AML cells.

Authors:  Qing Xu; James E Thompson; Martin Carroll
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 2.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

Authors:  Xiao Huang; Dongyun Li; Tiantian Li; B O Zhao; Xinyi Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

4.  Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Authors:  James Marvin; Suchitra Swaminathan; Geoffrey Kraker; Amy Chadburn; James Jacobberger; Charles Goolsby
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

5.  Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice.

Authors:  J Zhang; Y Xiao; Y Guo; P Breslin; S Zhang; W Wei; Z Zhang; J Zhang
Journal:  Leukemia       Date:  2011-09-16       Impact factor: 11.528

6.  PTEN's regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia.

Authors:  Cheng Zhiyong; Liang Wentong; Yang Xiaoyang; Pan Ling
Journal:  Med Oncol       Date:  2011-03-01       Impact factor: 3.064

7.  Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Authors:  N Sandhöfer; K H Metzeler; M Rothenberg; T Herold; S Tiedt; V Groiß; M Carlet; G Walter; T Hinrichsen; O Wachter; M Grunert; S Schneider; M Subklewe; A Dufour; S Fröhling; H-G Klein; W Hiddemann; I Jeremias; K Spiekermann
Journal:  Leukemia       Date:  2014-10-17       Impact factor: 11.528

8.  Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes.

Authors:  Olesea Cojohari; Megan A Peppenelli; Gary C Chan
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

9.  PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

Authors:  Nikolaos Patsoukis; Lequn Li; Duygu Sari; Victoria Petkova; Vassiliki A Boussiotis
Journal:  Mol Cell Biol       Date:  2013-06-03       Impact factor: 4.272

10.  PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.

Authors:  Raoul Tibes; Steven M Kornblau; Yihua Qiu; Spyro M Mousses; Christiane Robbins; Tracy Moses; John D Carpten
Journal:  Br J Haematol       Date:  2007-12-05       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.